Accuray

Accuray, Inc. is a radiation oncology company. It engages in the development, manufacture and sale of treatment solutions that includes CyberKnife and Tomo Therapy systems, designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image-guided radiation therapy, and adaptive radiation therapy. The company was founded by John R. Adler in 1990 and is headquartered in Sunnyvale, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Accuray reports strong Q1 2023 earnings and focuses on global expansion

Accuray's Q1 2023 earnings call highlighted strong financial performance, with significant revenue growth and increased system orders. The company is focused on driving profitability expansion and expanding patient access to its technologies worldwide. While facing challenges in managing backlog and addressing performance in China, Accuray is actively pursuing opportunities for margin expansion and business growth.

Accuray delivers record Q2 performance, eyes growth opportunities ahead

Accuray's Q2 2023 performance highlighted record system deliveries and strong order growth, with a focus on radiation oncology services.
Despite challenges in revenue decline and backlog, strategic wins and progress in key regions position the company for future growth.
Opportunities lie in market expansion in the Americas, strategic wins in key regions, and advancements in China.
Maintaining growth momentum, addressing revenue challenges, and capitalizing on opportunities are key focus areas for Accuray.

Accuray reports strong Q3 earnings, eyes global expansion and partnerships

Accuray's Q3 2023 earnings call showcased robust financial performance, strategic initiatives to drive profitability, and a commitment to global expansion. Despite challenges in product positioning and market competition, the company's focus on innovation and partnerships positions it well for future growth and market leadership.

Accuray reports 8% revenue growth, eyes margin expansion and growth

Accuray's Q4 2023 performance showed revenue growth, strong demand for Radixact, and strategic order wins. While facing challenges in product margins and supply chain, the company aims for margin expansion and growth opportunities in the second half of FY '24. Implementation of a new ERP system is expected to drive operational efficiencies and profitability insights.

Accuray reports strong Q1 earnings, eyes growth in China and India

Accuray delivered a robust Q1 performance with revenue and EBITDA growth, backed by strategic wins in key markets like China and India. The company's focus on new product innovations and cost optimization efforts contributed to its positive results. While challenges related to inflation exist, Accuray remains optimistic about reimbursement changes and market opportunities.

Accuray reports strong Q2 performance with growth opportunities ahead

Accuray's Q2 2024 showcased robust order growth, service revenue increase, and global demand strength. The company is focused on margin expansion and new product market clearances for future growth.

Accuray faces challenges in Q3 2024 but remains optimistic

Accuray's Q3 2024 performance was impacted by challenges but showed resilience with global order growth and strategic focus on long-term goals. Despite revised guidance, the company remains optimistic about future growth drivers and is prepared for gradual recovery post-COVID.

Accuray reports robust Q1 performance and raises FY '25 guidance

Accuray's Q1 2025 performance reflects strong revenue growth, margin expansion efforts, and positive market reception for its innovative products and services.
While facing challenges in certain markets and regulatory timelines, the company remains optimistic about future revenue trends and growth opportunities globally.
By raising its revenue guidance and focusing on operational efficiency, Accuray aims to capitalize on market opportunities and navigate potential challenges effectively.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Accuray, Inc. is a radiation therapy company, which engages in manufacturing medical equipment. It develops, manufactures, sells, and supports medical solutions. The company was founded by John R. Adler in 1990 and is headquartered in Madison, WI.

ARAY's first-quarter fiscal 2025 earnings meet estimates. Both the top and bottom lines deteriorate year over year.

Accuray Q1 Earnings Meet Estimates, Sales Beat, Gross Margin Shrinks

Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript

The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Accuray (ARAY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Accuray (ARAY) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.

Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates

Strong Start to Fiscal Year, Raises 2025 Guidance MADISON, Wis. , Nov. 6, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2024.

Accuray Reports Fiscal 2025 First Quarter Financial Results

MADISON, Wis., Oct. 23, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2025, ended September 30, 2024, during a conference call hosted by company management at 1:30 p.m.

Accuray to Report First Quarter Fiscal 2025 Financial Results on November 6, 2024

MADISON, Wis. , Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller.

Accuray Appoints Michael Murphy as VP, Corporate Controller

ARAY's solid product demand and revenue growth raise optimism about the stock.

Here's Why You Should Retain Accuray Stock in Your Portfolio Now

MADISON, Wis. , Oct. 15, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced that, effective as of today, Suzanne Winter has returned from her temporary medical leave and assumed her full duties as President and Chief Executive Officer.

Accuray President and Chief Executive Officer Suzanne Winter Returns from Medical Leave of Absence

Accuray is the first industry partner to open a facility at the Genolier Innovation Hub, created to provide opportunities for clinician-industry collaborations that can help accelerate improvements in patient care New Accuray CyberComm™ tool was used to significantly reduce the CyberKnife® S7™ System's commissioning time and enable product training in Genolier to begin more quickly MADISON, Wis. , Sept. 30, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the initiation of CyberKnife® S7™ System medical professional training at its education center located within the newly opened Genolier Innovation Hub, a fully-owned subsidiary of AEVIS VICTORIA SA, in Switzerland.

Accuray Celebrates Opening of Genolier Innovation Hub in Switzerland, Initiation of CyberKnife® S7™ System Medical Professional Training

The latest adoption of Accuray's Radixact System and VitalHold package is likely to improve the care provided to cancer patients and their experience.

ARAY Stock Up Following the Use of SGRT on Cancer Patients in Japan

The Technology Will Play an Important Role in the Hospital's Plan to Expand Patient Access to High Precision Radiation Therapy Treatments MADISON, Wis. , Sept. 10, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Gifu Prefectural General Medical Center is setting a new standard in cancer care in Japan as the first hospital in the country to treat patients with surface-guided radiation therapy (SGRT) using the company's Radixact ® Radiation Delivery System and VitalHold™* package.

Gifu Prefectural General Medical Center Achieves Milestone with Treatment of the First Cancer Patients in Japan Using the Accuray Radixact® System and VitalHold™ Solution

MADISON, Wis. , Sept. 3, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that President and Chief Executive Officer Suzanne Winter will be taking a temporary medical leave of absence to receive care for a treatable form of cancer, effective immediately.

Accuray President and Chief Executive Officer Suzanne Winter to Take Temporary Medical Leave of Absence

ARAY's Helix system, now CE Mark approved, aims to close global cancer care gaps with cost-effective, high-throughput radiotherapy for underserved regions.

Accuray Stock Rises After Helix System Wins CE Mark for Cancer Care

Developed for India and other countries where patient access to care with radiotherapy is challenged and where versatility and ease of use are a high priority Drives the next phase of company's strategic plan to expand its portfolio of helical radiation therapy delivery systems MADISON, Wis. , Aug. 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today the company has received CE Mark for Accuray Helix™, a CT-guided helical radiotherapy system designed to provide high-performance and high-throughput.

Accuray Receives CE Mark for a New Helical Radiation Delivery System, Accuray Helix™

Accuray posts a strong end to the fiscal year with 16% revenue growth in FQ4, beating expectations and restoring some confidence for the upcoming year. Management's claim that weaker U.S. sales are a consequence of a weaker capex environment don't fully align with the reported U.S. sales results of other med-tech capital equipment companies. Global opportunities remain promising, especially in China's value-priced linac market, and opportunities in Japan, India, other emerging markets are meaningful.

Accuray Remains A Perpetual 'Next Year Is Our Year' Story

Accuray's (ARAY) Radixact System with VitalHold technology is set to enhance precision and comfort in radiation therapy.

Accuray's (ARAY) Radixact for Cancer Treatment Debuts in US

Despite improving product sales, Accuray (ARAY) reports mixed fourth-quarter fiscal 2024 results.

Accuray (ARAY) Q4 Earnings Lag Estimates, Gross Margin Shrinks

Accuray Incorporated (NASDAQ:ARAY ) Q4 2024 Earnings Call Transcript August 14, 2024 4:30 PM ET Company Participants Jesse Chew - SVP and Chief Legal Officer Suzanne Winter - President and CEO Ali Pervaiz - CFO Conference Call Participants Young Li - Jefferies Marie Thibault - BTIG Brooks O'Neil - Lake Street Capital Markets Jason Wittes - Roth Capital Operator Good day, and welcome to the Accuray Fscal 2024 Fourth Quarter Financial Results Call. All participants will be in listen-only mode.

Accuray Incorporated (ARAY) Q4 2024 Earnings Call Transcript

14% Revenue and 8% Orders Growth in Q4; Company issues FY25 Guidance MADISON, Wis. , Aug. 14, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2024, ended June 30, 2024.

Accuray Reports Fourth Quarter and Fiscal 2024 Financial Results

New Technology Provides Advanced Patient Positioning Capabilities With the Radixact System, Making it Easier to Deliver Fast and Effective Radiotherapy Treatments MADISON, Wis. and DAYTONA BEACH, Fla.

Halifax Health in Florida is First in the U.S. to Treat Patients with Cancer Using the Accuray Radixact® Radiation Delivery System and VitalHold™ Technology

Accuray's (ARAY) solid product demand raises optimism about the stock.

Here's Why You Should Retain Accuray (ARAY) Stock for Now

MADISON, Wis. , July 31, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the fourth quarter of fiscal year 2024, ended June 30, 2024, during a conference call hosted by company management at 1:30 p.m.

Accuray to Report Fourth Quarter Fiscal 2024 Financial Results on August 14, 2024

Aurora Innovation

Globalstar

When it comes to investing in top penny stocks, a word of caution. Always do your due diligence before buying.

3 Penny Stock Lotto Tickets With 100X Potential

The Radixact System will be supplied with ClearRT®, Synchrony®, and the VOLO™ Ultra Optimizer to enhance radiation treatment delivery precision and speed Heidelberg University Hospital is recognized worldwide for excellence in patient care and practice changing research MADISON, Wis. , June 27, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that long-term customer Heidelberg University Hospital in Heidelberg, Germany, has selected the company's Radixact ® System, equipped with its proprietary ClearRT ®, Synchrony ® and VOLO™ Ultra Optimizer solutions, to help transform their approach to cancer care.

News for Accuray Stock (ARAY)